- Home
- MRCC vs SCPH Comparison
MRCC vs SCPH Comparison
Compare MRCC & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- SCPH
- Stock Information
- Founded
- MRCC 2011
- SCPH 2013
- Country
- MRCC United States
- SCPH United States
- Employees
- MRCC N/A
- SCPH N/A
- Industry
- MRCC Investment Managers
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- SCPH Health Care
- Exchange
- MRCC Nasdaq
- SCPH Nasdaq
- Market Cap
- MRCC 155.1M
- SCPH 299.0M
- IPO Year
- MRCC 2012
- SCPH 2017
- Fundamental
- Price
- MRCC $7.57
- SCPH $5.61
- Analyst Decision
- MRCC Hold
- SCPH Buy
- Analyst Count
- MRCC 1
- SCPH 3
- Target Price
- MRCC $8.00
- SCPH $12.00
- AVG Volume (30 Days)
- MRCC 66.0K
- SCPH 2.3M
- Earning Date
- MRCC 11-11-2025
- SCPH 11-12-2025
- Dividend Yield
- MRCC 13.42%
- SCPH N/A
- EPS Growth
- MRCC N/A
- SCPH N/A
- EPS
- MRCC 0.09
- SCPH N/A
- Revenue
- MRCC $51,229,000.00
- SCPH $49,969,000.00
- Revenue This Year
- MRCC N/A
- SCPH $108.95
- Revenue Next Year
- MRCC N/A
- SCPH $78.30
- P/E Ratio
- MRCC $84.33
- SCPH N/A
- Revenue Growth
- MRCC N/A
- SCPH 107.79
- 52 Week Low
- MRCC $5.96
- SCPH $1.94
- 52 Week High
- MRCC $8.85
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- MRCC 72.81
- SCPH 63.30
- Support Level
- MRCC $7.43
- SCPH $4.33
- Resistance Level
- MRCC $7.66
- SCPH $5.62
- Average True Range (ATR)
- MRCC 0.13
- SCPH 0.04
- MACD
- MRCC -0.02
- SCPH 0.00
- Stochastic Oscillator
- MRCC 76.92
- SCPH 78.57
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.